MicroVue™ C5a EIA
The MicroVue C5a Enzyme Immunoassay is for the measurement of C5a in human serum, plasma, and other biological or experimental samples.
Product Specifications
Citations | 57 |
---|---|
Specimen |
Serum 10 μL, EDTA or Citrated Plasma 20 μL |
LLOQ | 0.05 ng/mL |
ULOQ | N/A |
Assay Time | 2.5 hours |
Cross Reactivity |
None |
Ordering Information
Catalog Number | A021 |
---|---|
Catalog Number (CE) | A025 |
Size | 96 wells/test |
Price (USD) | $725.00 |
Price (EURO) | 640,00 € |
Contact us
US Phone | +1 (858) 552 1100 |
---|---|
EU Phone | +353 (91) 412 474 |
US Email | contact-us@quidelortho.com |
EU Email | contact-emea@quidelortho.com |
- Specifications
- Citations
- Certificate of Analysis
Specifications
Description |
The MicroVue C5a Enzyme Immunoassay is for the measurement of C5a in human serum, plasma, and other biological or experimental samples. |
---|---|
Size | 96 wells/test |
Form |
96 well plate with 12 eight-well strips in a resealable foil pouch |
Specimen | Serum 10 μL, EDTA or Citrated Plasma 20 μL |
Limit of Detection (LOD) | 0.01 ng/mL |
Lower Limit of Quantitation (LLOQ) | 0.05 ng/mL |
Upper Limit of Quantitation (ULOQ) | N/A |
Intra Assay | 3.5–3.9% |
Inter Assay | 7.1–13% |
Standards | 5 |
Controls | 2 |
Sample Values |
Serum 13.4–179.2 ng/mL, EDTA Plasma 0.37–74.3 ng/mL |
Assay Time | 2.5 hours |
Cross Reactivity |
None |
Storage |
Store the unopened kit at 2°C to 8°C. Refer to Product Insert for additional storage details. |
Background |
The MicroVue C5a Enzyme Immunoassay is a 96 well, direct-capture immunoassay for the measurement of C5a in human serum, plasma, and other biological or experimental samples. Under normal conditions, activation of the classical, alternative, or lectin complement pathways results in the formation of a C5 convertase multi-molecular enzyme capable of cleaving C5 to C5a and C5b. C5b is a key constituent of the Terminal Complement Complex and has a variety of functions in this role. C5a is a low molecular weight (approximately 9kD) protein fragment of 74 amino acids. C5a is rapidly metabolized by the serum enzyme carboxypeptidase to a more stable, less active, 73 amino acid form, C5a des-Arg. For convenience, both forms will be referred to as “C5a” for purposes of this documentation. The MicroVue C5a assay, which provides a rapid, highly specific and quantitative procedure for measuring C5a levels, is designed for investigations into the role or status of terminal complement pathway activation in numerous research settings, and for monitoring the generation of C5a in vivo or in vitro. As the most potent of the complement anaphylatoxins, C5a has a host of biologic functions including mast cell degranulation, chemotaxis, leukosequestration, as well as cellular activation via binding to the C5a Receptor (C5aR or CD88). Research has associated elevated levels of fluid phase and adsorbed C5a with hemo-incompatibility of some biomaterials, particularly in extracorporeal circuits. Research has also associated levels of C5a with pathogenesis of a variety of disease states including myocardial infarction, stroke, as well as vascular leak syndrome and associated kidney injury. The role of C5a in the pathogenesis of malaria20 and other infectious diseases, as well as sepsis, is likewise well documented. |
Citations
Title | Year | Applications | Sample Species | Sample | Sample Details |
---|---|---|---|---|---|
2016 | ELISA |
Human |
ARPE-19 Cells |
||
2017 | ELISA |
Human |
Plasma |
Hereditary Angioedema |
|
2018 | ELISA |
Human |
GMVEC cells, BMVEC cells |
||
2019 | ELISA |
Human |
Plasma |
ANCA-AAV |
|
Subvisible Particles in IVIg Formulations Activate Complement in Human Serum. |
2020 | ELISA |
Human |
Serum |
IVIg formulations |
Complement factor H contributes to mortality in humans and mice with bacterial meningitis. |
2019 | ELISA |
Human |
CSF |
Bacterial meningitis |
Complement Activation Profile of Patients With Primary Focal Segmental Glomerulosclerosis. |
2020 | ELISA |
Human |
Plasma |
FSGS |
Complement Activation Profile of Patients With Primary Focal Segmental Glomerulosclerosis. |
2020 | ELISA |
Human |
Serum |
FSGS |
2020 | ELISA |
Human |
Plasma |
COVID-19 |
|
Complement activation and endothelial perturbation parallel COVID-19 severity and activity. |
2020 | ELISA |
Human |
Plasma |
COVID-19 |
2020 | ELISA |
Human |
Serum |
Lupus Nephritis, Thrombotic Microangiopathy |
|
2020 | ELISA |
Human |
Urine |
Lupus Nephritis, Thrombotic Microangiopathy |
|
2021 | ELISA |
Human |
Serum |
COVID-19 |
|
von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study. |
2021 | ELISA |
Human |
Plasma |
C3G |
von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study. |
2021 | ELISA |
Human |
Urine |
C3G |
2021 | ELISA |
Human |
Plasma |
Thrombotic Microangiopathy - TA |
|
2021 | ELISA |
Human |
Plasma |
||
The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare. |
2021 | ELISA |
Human |
Plasma |
Lupus Nephritis |
Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19. |
2021 | ELISA |
Human |
Plasma |
Cancer, COVID-19 |
Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19. |
2021 | ELISA |
Human |
Plasma |
COVID-19 |
2022 | ELISA |
Human |
Plasma |
aHUS |
|
2022 | ELISA |
Human |
Plasma |
COVID-19 |
|
Human Neutrophils Respond to Complement Activation and Inhibition in Microfluidic Devices. |
2021 | ELISA |
Human |
Serum |
|
2022 | ELISA |
Human |
Plasma |
COVID-19 |
|
2022 | ELISA |
Human |
Serum |
COVID-19 |
|
2022 | ELISA |
Human |
Plasma |
Antiphospholipid syndrome |
|
2022 | ELISA |
Human |
Plasma |
Heat-related illnesses |
|
2022 | ELISA |
Human |
Serum |
Myeloperoxidase-ANCA-associated glomerulonephritis |
|
Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis. |
2022 | ELISA |
Human |
Urine |
AAV, FSGS, IgAN, MN, and LN |
2022 | ELISA |
Human |
Plasma |
Hemodialysis |
|
2022 | ELISA |
Human |
Serum |
CipA |
|
2023 | ELISA |
Human |
Plasma, Serum |
Glomerulonephritis |
|
2023 | ELISA |
Human |
Plasma |
Sepsis |
|
2011 | ELISA |
Human |
Serum |
||
Human pentraxin 3 binds to the complement regulator c4b-binding protein |
2011 | ELISA |
Human |
Fibroblasts |
|
A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function |
2012 | ELISA |
Human |
Serum |
GEnCs and HUVEC exposed |
Complement activation in pediatric patients with recurrent acute otitis media |
2013 | ELISA |
Human |
Ear Fluid (MEE) |
|
Complement activation in pediatric patients with recurrent acute otitis media |
2013 | ELISA |
Human |
Serum |
|
2013 | ELISA |
Human |
CSF |
||
2014 | ELISA |
Human |
Plasma |
Lupus Nephritis |
|
2014 | ELISA |
Human |
Plasma |
||
Defining the complement biomarker profile of C3 glomerulopathy |
2014 | ELISA |
Human |
Plasma |
C3G |
2015 | ELISA |
Human |
Plasma |
||
Cerebrospinal fluid inflammatory markers in patients with Listeria monocytogenes meningitis |
2014 | ELISA |
Human |
CSF |
Listeria meningitis |
2015 | ELISA |
Human |
Plasma |
||
2015 | ELISA |
Human |
Serum |
Porcine articular chondrocytes |
|
2015 | ELISA |
Human |
Plasma |
||
2015 | ELISA |
Human |
Serum |
||
Platelet-borne complement proteins and their role in platelet–bacteria interactions |
2016 | ELISA |
Human |
Plasma |
|
2016 | ELISA |
Human |
Serum |
||
Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation |
2016 | ELISA |
Human |
Plasma |
Imprime yeast treated |
VEGF regulates local inhibitory complement proteins in the eye and kidney |
2016 | ELISA |
Human |
Aqueous humour |
|
2017 | ELISA |
Human |
Serum |
Trauma, newborn brain |
|
2017 | ELISA |
Human |
Plasma |
||
2017 | ELISA |
Human |
Plasma |
ANCA-AAV |
|
rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs |
2018 | ELISA |
Human |
Serum |
Fc activation |
2024 | ELISA |
Human |
Urine |
FSGS, MCD |